SecBot SecBot
COURT-RULING ·Filed Jul 28, 2026

NVS

NOVARTIS AG
NEUTRAL
Impact 1/10
Horizonimmediate Processed3mo ago CourtCourt Ruling · govinfo.gov
Court ruling (district)
Actionable Insight • Neutral

This is a routine procedural order with no price impact. Monitor for future substantive rulings (e.g., claim construction, summary judgment, or trial) that could affect Novartis's patent positions or financial exposure.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$158.83
T+0 close · Jul 29, 2026 · via day close
Latest settled
−1.61%
T+60 · $156.27
Vs SPY
−6.34%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 29 $158.83entry
  2. T+1 · 4mo ago −0.25%α −1.92% · $158.44
  3. T+5 · 3mo ago −2.76%α −8.29% · $154.44
  4. T+20 · 3mo ago −0.81%α −5.83% · $157.54
  5. T+60 · 26d ago −1.61%α −6.34% · $156.27
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

A federal district court in the Northern District of California issued a routine order granting pro hac vice admission for an attorney representing Novartis Pharmaceuticals Corp. in a patent case (Regents of University of Michigan et al v. Novartis Pharmaceuticals Corporation). This is a purely procedural step with no ruling on the merits, damages, or injunctive relief. The ruling has no material impact on Novartis AG's business or stock.

Court Ruling Details

Ruling Date
Jul 28, 2026
Court
United States District Court for the Northern District of California
Court Level
District
Case Type
patent
Ruling Type
other
Precedent Risk
LOW

Key Facts

  • Order granted pro hac vice admission for plaintiff's attorney; no substantive ruling on liability or damages.
  • Case is a patent infringement dispute involving Regents of University of Michigan against Novartis Pharmaceuticals Corp.

Financial Impact

Not specified

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
50% bullish (34 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 court opinion.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-68f552434d-NVS

Track record

16 reports on NVS

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +6.86% at T+60 after the Jul 1, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 3/10 Entry $160.50 to $160.20 Now $160.20 −0.19% ▼ −0.19% +1.72% vs SPY
  2. Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $163.26 to $160.32 Now $160.20 −1.87% ▼ −1.80% −3.12% vs SPY
  3. Oct 28, 202619d ago 144 Neutral 2/10 Entry $156.08 to $161.10 Now $160.20 +2.64% ▲ +3.22% +3.60% vs SPY
  4. Oct 27, 202620d ago 6-K Mixed 6/10 Entry $156.86 to $156.08 Now $160.20 +2.13% ▼ −0.50% −0.84% vs SPY
  5. Oct 15, 20264w ago Court Ruling Neutral 2/10 Entry $150.62 to $150.20 Now $160.20 +6.36% ▼ −0.28% −0.70% vs SPY
  6. Oct 13, 20265w ago Court Ruling Bearish 5/10 Entry $146.88 to $150.38 Now $160.20 −9.07% ▼ −2.38% −2.10% vs SPY
  7. Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $141.28 to $142.71 Now $160.20 +13.39% ▲ +1.01% +1.73% vs SPY
  8. Sep 4, 202610w ago 6-K Bearish 6/10 Entry $137.70 to $137.48 Now $160.20 −16.34% ▲ +0.16% −0.30% vs SPY
  9. Sep 1, 202610w ago 6-K Bullish 7/10 Entry $161.25 to $162.46 Now $160.20 −0.65% ▲ +0.75% +0.31% vs SPY
  10. Aug 4, 202615w ago Court Ruling Neutral 2/10 Entry $154.44 to $154.21 Now $160.20 +3.73% ▼ −0.15% +0.01% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 8h 13m

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ Court Ruling · govinfo.gov Report published Jul 29, 2026